Literature DB >> 8840135

Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction.

M Gassen1, Y Glinka, B Pinchasi, M B Youdim.   

Abstract

Ergoline-derived dopamine receptor agonists, like pergolide or bromocryptine, have recently attracted attention as potential neuroprotective drugs. The classical mixed type dopamine D1 and D2 receptor agonist apomorphine, although used clinically in the therapy of Parkinson's disease, has never been examined for any properties related to neuroprotection. In this paper, we examine the effects of 0.1-100 microM apomorphine on ascorbate/iron-stimulated free radical processes in rat brain mitchondrial fraction. Lipid peroxidation as assayed by the thiobarbituric acid reaction can be completely inhibited by submicromolar concentrations of apomorphine (0.3 microM with 2.5 microM Fe2+ and 0.6 microM with 5.0 microM Fe2+), which proved to be more than twice as effective as desferrioxamine and twenty times as compared with dopamine. The inhibition of lipid peroxidation in mitochondria correlates with an increased rate of apomorphine oxidation. The formation of protein carbonyls, which is generally less sensitive to antioxidants, could be significantly reduced by apomorphine. In the model system we employed, apomorphine was more active than dopamine, desferrioxamine, or pergolide in preventing the formation of thiobarbituric reactive substances. The time course of the reaction suggests that apomorphine acts as a radical scavenger and that its iron chelating properties may not be of major importance. Since oxidative stress has been implicated in Parkinson's disease, the role of apomorphine as a neuroprotective is worthy of examination.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8840135     DOI: 10.1016/0014-2999(96)00291-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  22 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

2.  Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist.

Authors:  K Tanaka; I Miyazaki; N Fujita; M E Haque; M Asanuma; N Ogawa
Journal:  Neurochem Res       Date:  2001-01       Impact factor: 3.996

3.  Strategies for the protection of dopaminergic neurons against neurotoxicity.

Authors:  M Gerlach; K L Double; M B Youdim; P Riederer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

4.  Neuroprotective and neurorestorative strategies for neuronal injury.

Authors:  M F Beal; T Palomo; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

5.  Dopamine promotes the survival of embryonic striatal cells: involvement of superoxide and endogenous NADPH oxidase.

Authors:  Liping Ma; Jiawei Zhou
Journal:  Neurochem Res       Date:  2006-05-09       Impact factor: 3.996

6.  The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice.

Authors:  M B H Youdim; E Grünblatt; S Mandel
Journal:  J Neural Transm (Vienna)       Date:  2006-06-01       Impact factor: 3.575

Review 7.  Are dopamine receptor agonists neuroprotective in Parkinson's disease?

Authors:  W D Le; J Jankovic
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

8.  Dopamine agonists and analogues have an antiproliferative effect on CHO-K1 cells.

Authors:  R Maggio; M Armogida; M Scarselli; F Salvadori; B Longoni; C Pardini; A Chiarenza; S Chiacchio; F Vaglini; R Bernardini; A Colzi; G U Corsini
Journal:  Neurotox Res       Date:  2000-04       Impact factor: 3.911

Review 9.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

10.  Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole.

Authors:  Giulia Ferrari-Toninelli; Giuseppina Maccarinelli; Daniela Uberti; Erich Buerger; Maurizio Memo
Journal:  BMC Pharmacol       Date:  2010-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.